suboxone_sl_tabs

Indivior shares fall by 70% after allegations of fraud

pharmafile | April 10, 2019 | News story | Research and Development Virginia, indivior, opioid crisis, opioids, suboxone 

Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to the dangers of its Suboxone opioid addiction treatment.

Indivior were alleged to have used their ‘Here to Help’ program “to connect patients to doctors it knew were prescribing Suboxone and other opioids to more patients than allowed by federal law, at high doses, and in suspect circumstances.”

The indictment, filed in Virginia, said patients were pointed towards doctors who prescribed opioids in a “careless and clinically unwarranted manner” as part of an effort to boost sales.

The indictment contains 28 counts of felony including one count of conspiracy to commit mail, wire and health care fraud; one count of health care fraud; four counts of mail fraud; and twenty-two counts of wire fraud.

In a statement to the stockmarket, Indivior said the allegations were “based on actions that occurred almost exclusively prior to Indivior becoming an independent company in its demerger from Reckitt Benckiser Group at the end of 2014.”  

Shares in Indivior fell by as much as 70% on announcement of the news. Shares in the Reckitt Benckiser Group were down 6%.

The Reckitt Benckiser Group was clear in stating: “This indictment is not against RB Group or any other group company.” Meanwhile Indivior said the allegations were “unsupported by the facts and the law.”

Louis Goss

Related Content

FDA approves prescription nasal spray for opioid overdose treatment

The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the …

shutterstock_512649

Johnson & Johnson to contribute a further $1 billion to US opioid settlement

Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the …

800px-jnjioffice

New York files $2 billion lawsuit against J&J for downplaying risks of opioids in its marketing

New York State is suing Johnson & Johnson in a lawsuit seeking $2 billion in …

Latest content